



Published on *Puma Biotechnology Investor Center* (<https://investor.pumabiotechnology.com>) on 12/16/15 1:15 pm PST

# **Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea**

## **Release Date:**

Wednesday, December 16, 2015 1:15 pm PST

## **Terms:**

## **Dateline City:**

LOS ANGELES

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, will host a conference call and slide presentation to discuss preliminary results of its Phase II study looking at the incidence and severity of diarrhea in patients with early-stage HER2-positive breast cancer treated with extended adjuvant neratinib monotherapy and prophylactic loperamide. The call will be held at 4:15 p.m. EST (1:15 p.m. PST) on December 21, 2015.

The live call may be accessed by dialing 877-709-8150 for domestic callers and 201-689-8354 for international callers. Please specify to the operator that you would like to join the "Puma Biotechnology Update Call." A live webcast of the call and presentation slides will be available online on the investor relations section of the company website at [http://www.pumabiotechnology.com/ir\\_events.html](http://www.pumabiotechnology.com/ir_events.html) and will be archived there for 30 days following the call. Please visit Puma's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

## **About Puma Biotechnology**

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the acquisition, development and commercialization of innovative products to enhance cancer care. The Company aims to acquire proprietary rights to these products, by license or otherwise, fund their research and development and bring the products to market. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation.

Further information about Puma Biotechnology may be found at [www.pumabiotechnology.com](http://www.pumabiotechnology.com).

## **Forward-Looking Statements:**

This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

## **Language:**

English

## **Contact:**

Puma Biotechnology, Inc.  
Alan H. Auerbach or Mariann Ohanesian, +1 424 248 6500  
[info@pumabiotechnology.com](mailto:info@pumabiotechnology.com)  
[ir@pumabiotechnology.com](mailto:ir@pumabiotechnology.com)  
or  
Russo Partners  
Robert Flamm or David Schull, +1 212 845 4226  
[robert.flamm@russopartnersllc.com](mailto:robert.flamm@russopartnersllc.com)  
[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

## **Ticker Slug:**

*Ticker:* PBYI

*Exchange:* NYSE

*ISIN:*

US74587V1070

---

**Source URL:** <https://investor.pumabiotechnology.com/press-release/puma-biotechnology-host-conference-call-discuss-loperamide-prophylaxis-reduce-neratini>